Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (638)	3/19/2004 6:20:38 PM
From: tuck	Read Replies (1) \| Respond to of 897

Times still tough for the BSCP, but a couple of positions are getting near a little profit. One is CHIR: >>8:32AM Chiron discontinues Tezacitabine program based on analysis of Phase II results (CHIR) 46.85: Co announces that it has decided to discontinue further development of tezacitabine, a next-generation nucleoside analog, based on an analysis of the data from a Phase II trial in patients with gastroesophageal cancer. The compound did not demonstrate sufficient antitumor activity in the trial to satisfy Chiron's predetermined criteria to advance the program. The company had previously announced that it had concluded Phase II development of tezacitabine in patients with colorectal cancer. "Data from the Phase II trial failed to meet Chiron's threshold for moving the program forward."<< Any suggestions? OSIP? Cheers, Tuck